256 completed, 65 terminated, 61 recruiting, 42 unknown. 506 Phase 2, 104 Phase 1, 39 Phase 3.
Follow Anemia, Hemolytic: new trials by email Literature Review of Anemia, Hemolytic trials Research Report on Anemia, Hemolytic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy NM8074 - aHUS - Atypical Hemolytic Uremic Syndrome | Phase 2 | Not yet recruiting | NovelMed Therapeutics | 12 | 2027-11-01 | 2026-04-13 |
| Study of NM8074 in Adult PNH Patients With Inadequate Response to Soliris NM8074, Soliris - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Not yet recruiting | NovelMed Therapeutics | 12 | 2027-01-01 | 2026-04-13 |
| A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA Velinotamig specified dose on specified days. - Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA) | Phase 1 / Phase 2 | Not yet recruiting | Cullinan Therapeutics Inc. | 72 | 2026-12-01 | 2026-07-31 |
| Feasibility and Acceptability of Amani Amani - Sickle Cell Disease | Phase 1 / Phase 2 | Not yet recruiting | Massachusetts General Hospital | 40 | 2026-11-01 | 2026-08-07 |
| Study of SGB-9768 in Patients With Paroxysmal Nocturnal Hemoglobinuria SGB-9768 - PNH - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Not yet recruiting | Suzhou Sanegene Bio Inc. | 24 | 2026-10-31 | 2026-09-04 |
| Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults Sub-dissociative Ketamine Infusion, Normal Saline Placebo Infusion - Sickle Cell Disease, Vaso-Occlusive Pain Episode in Sickle Cell Disease | Phase 2 | Recruiting | Mohsen Saidinejad | 120 | 2026-09-10 | 2026-09-02 |
| Gene Therapy for Patients With Transfusion-Dependent β-Thalassemia HGI-001 Injection - Beta Thalassemia Transfusion Dependent | Phase 2 | Not yet recruiting | Prince of Wales Hospital, Shatin, Hong Kong | 6 | 2026-09-01 | 2026-07-23 |
| Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease Cyclophosphamide 50mg, Abatacept, Alemtuzumab - Sickle Cell Disease | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 45 | 2026-09-01 | 2026-07-23 |
| Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE) BMS-986353, Fludarabine Phosphate, Cyclophosphamide - Chronic Immune Thrombocytopenia, Autoimmune Hemolytic Anemia | Phase 2 | Not yet recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 52 | 2026-08-31 | 2026-07-09 |
| Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype Senicapoc, Placebo - Sickle Cell Disease, Sickle Cell Anaemia | Phase 2 | Recruiting | Biossil Inc. | 105 | 2026-08-13 | 2026-08-17 |
| Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors Total Body Irradiation, Alemtuzumab, Abatacept - Sickle Cell Disease, Beta-thalassemia | Phase 1 / Phase 2 | Recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 90 | 2026-07-08 | 2026-10-13 |
| Dexamethasone, Intravenous Injection of Human Immunoglobulin, and Increased Infusion of Mononuclear Cells to Reduce Donor Specific Antibodies in Haploidentical Hematopoietic Stem Cell Transplantation Intravenous Immunoglobulin, Dexamethasone, Mononuclear Cells - Leukemia, Lymphoma | Phase 2 | Not yet recruiting | Hematology department of the 920th hospital | 60 | 2026-07-03 | 2026-07-14 |
| A Study of SNH-119014 in Adult Participants With Non-transfusion-dependent Thalassemia (NTDT) SNH-119014 dose 1, SNH-119014 dose 2, Placebo - Thalassemia | Phase 2 | Not yet recruiting | ScinnoHub Pharmaceutical Co., Ltd. | 30 | 2026-06-18 | 2026-05-12 |
| Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease Ruxolitinib - Sickle Cell Disease, Hematopoetic Stem Cell Transplant | Phase 1 / Phase 2 | Recruiting | Arkansas Children's Hospital Research Institute | 24 | 2026-06-08 | 2026-06-04 |
| STEM CELL MOBILIZATION WITH HIGH-DOSE PLERIXAFOR IN PATIENTS WITH SICKLE CELL DISEASE Plerixafor Dose Escalation - Sickle Cell Disease | Phase 1 / Phase 2 | Not yet recruiting | Hospital Israelita Albert Einstein | 12 | 2026-06-01 | 2026-01-14 |
| Study of NM8074 in Soliris-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) NM8074 - PNH - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Not yet recruiting | NovelMed Therapeutics | 6 | 2026-06-01 | 2025-03-30 |
| Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study hydroxycarbamide - Sickle Cell Disease, Sickle Cell Anemia in Children | Phase 1 / Phase 2 | Recruiting | Children's Hospital Medical Center, Cincinnati | 250 | 2026-05-13 | 2026-07-16 |
| Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin Empagliflozin (oral) - Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Albuminuria | Phase 2 | Recruiting | University of Illinois at Chicago | 20 | 2026-04-08 | 2026-05-19 |
| Study of Efficacy and Safety of NM8074 in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy NM8074 - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Not yet recruiting | NovelMed Therapeutics | 12 | 2026-04-01 | 2025-03-11 |
| Open-Label Extension Study to Pioneer Study 6058-SCD-101 Pociredir - Sickle Cell Disease | Phase 2 | Terminated | Fulcrum Therapeutics | 1 | 2026-03-30 | 2026-10-28 |
Showing 20 of 506. Sign in to see all of them.
Anemia, Sickle Cell (293) · beta-Thalassemia (87) · Thalassemia (71) · Hemoglobinuria, Paroxysmal (70) · Anemia (33) · Hemoglobinopathies (28) · Vaso-Occlusive Crises (27) · Hematologic Diseases (25) · Anemia, Aplastic (24) · Anemia, Hemolytic, Autoimmune (24) · Iron Overload (21) · Anemia, Diamond-Blackfan (20) · Myelodysplastic Syndromes (17) · Genetic Diseases, Inborn (16)
Hemic and Lymphatic Diseases (505) · Hematologic Diseases (481) · Anemia (473) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (398) · Anemia, Hemolytic, Congenital (390) · Genetic Diseases, Inborn (382) · Hemoglobinopathies (358) · Bone Marrow Diseases (97) · Pathological Conditions, Signs and Symptoms (85) · Thalassemia (67) · Myelodysplastic Syndromes (62) · Pathologic Processes (61) · Immune System Diseases (58) · Nutritional and Metabolic Diseases (51)
Hydroxyurea (44) · Cyclophosphamide (32) · Alemtuzumab (30) · Sirolimus (24) · fludarabine (23) · fludarabine phosphate (23) · Deferasirox (22) · Whole-Body Irradiation (21) · Busulfan (20) · Mycophenolic Acid (15) · eculizumab (15) · Melphalan (14) · Tacrolimus (14) · thymoglobulin (13) · Deferoxamine (12)
Novartis Pharmaceuticals (23) · National Heart, Lung, and Blood Institute (NHLBI) (20) · Alexion Pharmaceuticals, Inc. (16) · St. Jude Children's Research Hospital (13) · Children's Hospital Medical Center, Cincinnati (9) · Assistance Publique - Hôpitaux de Paris (8) · UCSF Benioff Children's Hospital Oakland (8) · Ain Shams University (6) · Emory University (6) · Institute of Hematology & Blood Diseases Hospital, China (6) · Johns Hopkins University (6) · University of North Carolina, Chapel Hill (6) · Agios Pharmaceuticals, Inc. (5) · Baylor College of Medicine (5) · BioCryst Pharmaceuticals (5)
United States (296) · United Kingdom (75) · Italy (59) · Canada (48) · France (46) · China (36) · Lebanon (32) · Turkey (Türkiye) (26) · Germany (25) · Thailand (20) · Greece (19) · Egypt (15) · Netherlands (15) · South Korea (14) · Spain (14)
Claudia Morris, MD (4) · John F Tisdale, M.D. (4) · Kenneth I Ataga, MD (4) · Damiano Rondelli, MD (3) · Dr. Anita Hill (3) · Mark Walters (3) · Mitchell S Cairo, MD (3) · Russell Ware, MD, PhD (3) · A O Dosunmu, M.D. (2)
PMID 36240296, PMID 33783815, PMID 37975597, PMID 42133908, PMID 23738544, PMID 34175041, PMID 37254256, PMID 38775255, PMID 40569673, PMID 29931453, PMID 32384147, PMID 33283989, PMID 34922648, PMID 36355805, PMID 36529836, PMID 36860093, PMID 36975201, PMID 38866240, PMID 40010689, PMID 41026975, PMID 41124654, PMID 41809202, PMID 41871072, PMID 41954645, PMID 42224366, PMID 42549972, PMID 14550808, PMID 17233848, PMID 18192510, PMID 18550258, PMID 19208097, PMID 20007560, PMID 20421452, PMID 20634373, PMID 20841509, PMID 20955402, PMID 21173101, PMID 21222185, PMID 21275961, PMID 21364138, PMID 21393329, PMID 21477202, PMID 21527519, PMID 21700776, PMID 21742281, PMID 21877169, PMID 21900080, PMID 22129980, PMID 22251482, PMID 22571408
2014 (8), 2016 (7), 2018 (7), 2017 (6), 2023 (6), 2019 (4), U01HL065238 (4), 2015 (3), 2025 (2), K24AT009893 (2), P30CA015704 (2), P30CA033572 (2), U10HL069294 (2), U24CA076518 (2), U54HL070587 (2)